nivolumab,ipilimumab
bms
['cm-914', 'nivo', 'nivolumab', 'renal,(-adrenal)', 'ipilimumab']
cm-914: adjuvant nivolumab plus ipilimumab versus placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: 6 months nivo-ipi did not met primary endpoint! no difference in dfs at 24 months #esmo22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni